# Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy

- Link: https://www.thailand-business-news.com/pr-news/akesos-next-generation-her3-adc-ak138d1-combined-with-ivonescimab-first-patient-enrolled-in-phase-ib-ii-breast-cancer-study-advancing-the-io2-0-adc2-0-strategy
- Published: 2026-06-15T13:52:00+07:00
- Author: PR Newswire

HONG KONG, June 15, 2026 /PRNewswire/ — Akeso, Inc. (HKEX: 9926) today announced
that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-
202) evaluating its internally developed next-generation HER3 antibody-drug conjugate(
ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the 
treatment of advanced breast cancer.

HER3 is broadly expressed across various solid tumors, including breast, ovarian,
colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients
globally. While traditional HER3-targeted ADCs have demonstrated therapeutic potential
in combination settings, their clinical utility has historically been constrained
by dose-limiting toxicities.

AK138D1 is a next-generation, differentiated HER3-targeting ADC developed in-house
by Akeso. Leveraging a unique, innovative design, AK138D1 is engineered to reduce
uptake in normal tissues, thereby minimizing off-target toxicities and widening 
the therapeutic window. Furthermore, its design prevents the clustering of ADC molecules
on the tumor surface, enhancing deep tissue penetration and uniform distribution
to overcome the "binding site barrier". Early-stage clinical studies conducted in
China and Australia have demonstrated that AK138D1 exhibits robust anti-tumor activity
in solid tumors and breast cancer, coupled with an excellent safety profile, notably
characterized by low hematologic toxicity and the absence of interstitial lung disease(
ILD). This compelling balance of efficacy and safety overcomes common limitations
of conventional ADCs, establishing a foundation for AK138D1 to be explored in diverse
combination therapeutic regimens.

The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest
unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which 
accounts for approximately 65% of all breast cancers, and triple-negative breast
cancer (TNBC), which represents 10-20% of cases. The trial enrolls patients across
multiple treatment lines from treatment-naïve to heavily pretreated, and includes
diverse PD-L1 expression levels. Breast cancer remains the most common cancer among
women worldwide, with an estimated 2.3 million new cases diagnosed annually. Substantial
unmet needs persist in both first-line and later-line settings for HR+/HER2- breast
cancer and TNBC.

Early data from AK138D1 studies have already shown meaningful efficacy and a strong
safety profile in breast cancer. Concurrently, a Phase III study of ivonescimab-
based combination therapy in first-line TNBC is ongoing. The combination of AK138D1
and ivonescimab is poised to emerge as a highly differentiated "IO2.0 + ADC2.0" 
therapeutic strategy for advanced breast cancer.

As IO+ADC combinations become a cornerstone of global oncology research, Akeso is
strategically and efficiently building a comprehensive global portfolio of these
next-generation therapies, leveraging its proprietary leadership in bispecific and
multispecific antibody platforms.

On the IO front, Akeso stands as the only company globally with two approved bispecific
antibodies for oncology, spearheading the advancement of IO2.0 therapies. Regarding
its ADC pipeline, Akeso’s development of AK146D1 (a Trop2/Nectin4 bispecific ADC)
and AK138D1, among other innovations, aims to resolve the toxicity-related limitations
of current ADCs and propel the field into the "ADC2.0" era.

**About AK138D1**

Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully
humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase
I inhibitor DXd through a cleavable linker, MC-AAA (maleimide-alanine-alanine-alanine).
After binding to HER3 on tumor cells, the ADC is internalized into the tumor cells,
where the linker is cleaved, releasing the membrane-permeable DXd. This leads to
DNA damage and subsequent cell apoptosis. Early study results have shown that AK138D1
possesses potent biological activity and a favorable safety profile. A phase II 
clinical trial is currently ongoing to investigate AK138D1 combined with cadonilimab
and ivonescimab in patients with solid tumors. This regimen is a critical part of
Akeso’s IO2.0 + ADC 2.0 combination approach.

**About Akeso**

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research,
development, manufacturing and commercialization of the world’s first or best-in-
class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive
R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-
Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology
platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
commercialization system, Akeso has developed into a globally competitive biopharmaceutical
enterprise. Leveraging its fully integrated, multi-functional platform, the company
maintains a robust pipeline of more than 50 innovative assets targeting cancer, 
autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic
areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific
or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached
commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources
to develop transformative medicines, deliver high-quality, affordable therapeutic
antibodies to patients worldwide, and generate sustained commercial and societal
value as it strives to become a global leader in biopharmaceutical innovation.

**Forward-Looking Statements**

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements".
These statements reflect the current beliefs and expectations of Akeso’s management
and are subject to significant risks and uncertainties. These statements are not
intended to form the basis of any investment decision or any decision to purchase
securities of Akeso. There can be no assurance that the drug candidate(s) indicated
in this announcement or Akeso’s other pipeline candidates will obtain the required
regulatory approvals or achieve commercial success. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions
and competition; general economic factors, including interest rate and currency 
exchange rate fluctuations; the impact of pharmaceutical industry regulation and
health care legislation in P.R.China, the United States and internationally; global
trends toward health care cost containment; technological advances, new products
and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Akeso’s ability to accurately predict future
market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the
Akeso’s patents and other protections for innovative products; and the exposure 
to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking
statements to reflect events or circumstances after the date hereof, except as required
by law.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy ](http://www.prnasia.com/story/archive/4983414_CN83414_0?rand=184833)
